(MedPage Today) — CHICAGO — Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major…
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery Disease Read More »
Compounding pharmacies faced a major setback in their case over the FDA’s decision to remove the obesity drug tirzepatide from its official shortage list.
The US District Court for the Northern District of Texas denied …
Federal judge denies preliminary injunction in tirzepatide compounding case Read More »
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more…
Novo Nordisk’s Ozempic successor disappointed Wall Street again Read More »
Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why
Ozempic is increasingly being linked to vision loss. What’s the truth? Read More »
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance.
Makers of Wegovy and Zepbound cut prices for those without insurance Read More »
FRIDAY, March 7, 2025 — The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Novo Nordisk, the Danish company behind Wegovy…
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance Read More »
Studies suggest types of fasting can lead to moderate weight loss and other health benefits in overweight and obese people, but only some doctors use it. Medscape Medical News
Is Intermittent Fasting Worth Considering for Your Patients? Read More »
